SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,278,000 | -86.8% | 1,200,000 | -67.6% | 0.68% | -85.3% |
| Q2 2023 | $77,625,979 | -0.9% | 3,708,838 | 0.0% | 4.64% | -18.3% |
| Q1 2023 | $78,330,659 | -17.0% | 3,708,838 | 0.0% | 5.67% | -3.4% |
| Q4 2022 | $94,389,927 | +15.1% | 3,708,838 | +8.7% | 5.87% | -7.1% |
| Q3 2022 | $82,010,000 | +33.4% | 3,412,838 | +6.8% | 6.32% | +8.8% |
| Q2 2022 | $61,480,000 | +10.7% | 3,195,403 | 0.0% | 5.80% | +22.6% |
| Q1 2022 | $55,536,000 | – | 3,195,403 | – | 4.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |